Importance Clinical outcomes after curative treatment of resectable pancreatic ductal
adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of …

Purpose Adjuvant chemotherapy improves patient survival rates after resection for
pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is …

Background Data on perioperative chemotherapy in resectable pancreatic ductal
adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant …

Background Outcomes of neoadjuvant systemic therapy versus an upfront operation for
clinical, stage III pancreatic adenocarcinoma remain poorly defined. Our aim was to …

Background Multiple trials have demonstrated a survival benefit for adjuvant chemotherapy
after resection of pancreatic adenocarcinoma. This study aimed to identify the rate for …

Background Despite major improvements in the perioperative outcome of pancreas surgery,
the prognosis of pancreatic cancer after curative resection remains poor. Adjuvant …

Background Pancreatic cancer is the fourth leading cause of cancer-related death. While
surgical resection remains the foundation for potentially curative treatment, survival benefit is …

Importance The prognosis for patients with pancreatic cancer is poor, even after resection
with curative intent. Gemcitabine-based chemotherapy is standard treatment for advanced …

Background The purpose of this study was to evaluate a single-institution experience with
delivery of preoperative therapy to patients with pancreatic ductal adenocarcinoma (PDAC) …

Importance The patterns of disease recurrence after resection of pancreatic ductal
adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns …